Korea Stock Market Insights

Tag: Biotech

  • Onconik Therapeutics IR Analysis: Zastaprazan Growth Momentum and Nesuparib Clinical Expectations

    Onconik Therapeutics IR Analysis: Zastaprazan Growth Momentum and Nesuparib Clinical Expectations 대표 차트 이미지

    1. Onconik Therapeutics IR: What to Expect

    Onconik Therapeutics will hold an investor relations (IR) meeting on September 8th at 9:00 AM. This IR, part of a Non-Deal Roadshow (NDR), aims to enhance corporate value by providing updates on business performance, current status, and a Q&A session. Key information disclosures are expected, including Zastaprazan sales growth, Nesuparib clinical trial progress, and future business plans.

    2. Why Pay Attention?: Growth Driver Analysis

    • Zastaprazan Growth: The successful launch of Zastaprazan for erosive esophagitis and the additional approval for gastric ulcer treatment are expected to drive sales growth. Technology transfer agreements with China, India, and South America have also secured a foundation for royalty revenue.
    • Nesuparib Clinical Expectations: Clinical development of the anticancer drug Nesuparib for pancreatic cancer, endometrial cancer, and other major cancers is progressing smoothly. Its designation as an orphan drug increases the likelihood of development and approval.
    • Solid Financial Structure: Onconik successfully raised capital through its KOSDAQ listing and maintains a stable financial structure with KRW 45.1 billion in cash and cash equivalents.

    3. Post-IR Stock Outlook and Investment Strategy

    Stock prices may fluctuate in the short term depending on the information disclosed at the IR. Positive information may create upward momentum, but failure to meet expectations could lead to selling pressure. In the mid-to-long term, Zastaprazan’s sales growth and the success of Nesuparib’s clinical trials will be key factors determining the stock’s trajectory. Investors should carefully analyze the IR content, future performance trends, and clinical results before making investment decisions.

    4. Action Plan for Investors

    If you are considering investing in Onconik Therapeutics, thoroughly review the information presented at the IR and the key points to watch. It is crucial to continuously monitor Zastaprazan sales, Nesuparib clinical results, and potential further technology transfer agreements. Changes in macroeconomic indicators, such as interest rates and exchange rates, should also be considered in your investment decision.

    What are Onconik Therapeutics’ main business areas?

    Onconik Therapeutics focuses on developing innovative new drugs for acid-related gastrointestinal diseases and cancer.

    What conditions is Zastaprazan used to treat?

    Zastaprazan is a P-CAB class drug used to treat erosive esophagitis and gastric ulcers.

    What stage of clinical trials is Nesuparib currently in?

    Nesuparib is currently undergoing clinical trials for several major cancers, including pancreatic and endometrial cancer, and has been designated as an orphan drug.

    When is Onconik Therapeutics’ IR scheduled?

    Onconik Therapeutics’ IR is scheduled for September 8, 2025, at 9:00 AM.

    Onconik Therapeutics IR Analysis: Zastaprazan Growth Momentum and Nesuparib Clinical Expectations 관련 이미지
    Onconik Therapeutics IR Analysis: Zastaprazan Growth Momentum and Nesuparib Clinical Expectations 관련 이미지

  • Naibek IR: Deep Dive into Growth Strategy After $430M Licensing Deal!

    Naibek IR: Deep Dive into Growth Strategy After $430M Licensing Deal! 대표 차트 이미지

    1. Naibek IR: What to Expect?

    On September 23, 2025, at 9:00 AM, Naibek will hold an investor relations (IR) session. The company will provide a detailed overview of its business, key pipeline updates, and future growth strategies. Investors are particularly eager for details regarding the recently announced licensing agreement with a US biopharmaceutical company.

    2. Why Naibek?

    Naibek has established a stable foundation in the dental bone graft material market and is driving innovative growth through the development of peptide-based pharmaceuticals.

    • $430M Licensing Agreement: The licensing of NP-201 (peptide fibrosis treatment) validates Naibek’s technological prowess. The substantial milestone and royalty payments will strengthen their financial position and accelerate future R&D efforts.
    • Diverse Pipeline: With a pipeline of peptide treatments for various diseases including fibrosis, obesity, and sarcopenia, Naibek demonstrates high growth potential.
    • CDMO Business Expansion: The establishment of GMP facilities for peptide APIs marks their entry into the CDMO market, creating a new revenue stream.

    Their 2025 semi-annual report highlights strong financial performance, including increased revenue and a return to profitability, signaling continued growth.

    3. The Impact of the IR

    This IR is expected to positively impact investor sentiment and potentially re-evaluate Naibek’s corporate value. Providing details on the licensing agreement and increasing pipeline visibility can enhance investor confidence. However, failing to meet market expectations or providing unsatisfactory responses to unexpected questions could lead to short-term stock volatility.

    4. Investor Action Plan

    If you are considering investing in Naibek, carefully review the information presented during the IR and focus on the following:

    • Specific terms and future plans for the NP-201 licensing agreement
    • Development status and market competitiveness of each pipeline candidate
    • Detailed growth strategy for the CDMO business

    Focus on the company’s long-term growth potential rather than short-term stock fluctuations, and continuously monitor macroeconomic conditions and market trends.

    What are Naibek’s main businesses?

    Naibek’s main businesses include dental bone graft materials, peptide drug development, and CDMO services for peptide APIs.

    What is Naibek’s core technology?

    Naibek’s core technology is PEPTARDEL, a peptide-based drug development platform.

    What is Naibek’s future growth strategy?

    Naibek aims to achieve sustainable growth through the expansion of its peptide drug pipeline and the launch of its CDMO business.

    Naibek IR: Deep Dive into Growth Strategy After $430M Licensing Deal! 관련 이미지
    Naibek IR: Deep Dive into Growth Strategy After $430M Licensing Deal! 관련 이미지

  • Next Biomedical IR Analysis: September 8, 2025, Securing Growth Momentum?



    Next Biomedical IR Analysis: September 8, 2025, Securing Growth Momentum? 대표 차트 이미지






    1. Next Biomedical IR: What was discussed?

    Next Biomedical presented its key management status and business progress, followed by a Q&A session with investors on September 8, 2025. The core focus of this IR was Nexpowder™’s global market expansion strategy, Nexsphere™-F’s US FDA approval and market entry roadmap, and plans for profitability improvement.

    2. Key Analysis: Why is it important?

    • Continued Nexpowder™ Growth: Sales reached 6.544 billion KRW in the first half of 2025, a 20.98% increase year-over-year, with plans to accelerate global expansion through US FDA approval and the Medtronic partnership.
    • Nexsphere™-F FDA Approval Expectations: Expectations for US market entry are rising with the US FDA Breakthrough Device Designation and Medicare approval.
    • Profitability Improvement Challenges: Improving the deficit structure due to high R&D and SG&A expenses is urgent.

    3. Future Outlook and Investment Strategy: What should investors do?

    Next Biomedical possesses an innovative product portfolio, but securing profitability is a critical challenge. Investors should carefully review the feasibility of the profitability improvement strategies presented at the IR, the speed of Nexpowder™’s global market expansion, and the roadmap for Nexsphere™-F’s FDA approval and market entry.

    4. Action Plan for Investors

    • Analyze IR materials and management responses
    • Refer to securities firm reports (to be published)
    • Evaluate company value and make investment decisions


    Frequently Asked Questions

    What is Next Biomedical’s main product?

    Next Biomedical’s main product is Nexpowder™, an endoscopic hemostatic agent.

    What is Next Biomedical’s Nexsphere™-F?

    Nexsphere™-F is a vascular embolization microsphere and a fast-degradable pain embolization therapeutic agent. It has received the US FDA Breakthrough Device Designation and Medicare approval.

    What were Next Biomedical’s sales in the first half of 2025?

    Next Biomedical’s sales in the first half of 2025 were 7.745 billion KRW, a 50.93% increase year-over-year.

    What are the main risks for Next Biomedical?

    The main risks for Next Biomedical are the continuous deficit structure due to high R&D and SG&A expenses, and the history of unmet 2024 forecasts.









    Next Biomedical IR Analysis: September 8, 2025, Securing Growth Momentum? 관련 이미지
    Next Biomedical IR Analysis: September 8, 2025, Securing Growth Momentum? 관련 이미지




  • FutureChem’s Prostate Cancer Drug Enters Phase 3 Trial: Investment Analysis

    FutureChem's Prostate Cancer Drug Enters Phase 3 Trial: Investment Analysis 대표 차트 이미지

    1. What Happened? ([177Lu]Ludotadipep Phase 3 Trial Approval)

    On September 4, 2025, FutureChem announced the approval of its Phase 3 clinical trial plan for [177Lu]Ludotadipep targeting metastatic castration-resistant prostate cancer (mCRPC) patients. This trial will be conducted in South Korea and will compare the efficacy and safety of [177Lu]Ludotadipep combined with best supportive care/standard of care (BSC/SoC) against BSC/SoC alone. The primary endpoint is radiological progression-free survival (rPFS).

    2. Why Does It Matter? (Impact on Corporate Value and Stock Price)

    The entry of [177Lu]Ludotadipep, FutureChem’s key pipeline, into Phase 3 clinical trials significantly increases the likelihood of commercialization. Successful clinical results are expected to boost investor confidence and reaffirm FutureChem’s R&D capabilities and market competitiveness. Considering the high growth potential of the prostate cancer treatment market, this approval is projected to have a substantial positive impact on FutureChem’s corporate value. However, potential risks such as clinical trial uncertainties, high R&D costs, and intensifying market competition should also be considered.

    3. What Should Investors Do? (Action Plan)

    While a positive short-term stock price trend is anticipated, long-term investors should closely monitor the Phase 3 clinical trial results and the subsequent commercialization process. Key factors to monitor include:

    • • Progress and interim results of the Phase 3 clinical trial
    • • Application and approval status for [177Lu]Ludotadipep
    • • Clinical progress of other pipelines (Alzheimer’s, Parkinson’s disease, etc.)
    • • News regarding technology transfer or partnership agreements
    • • Changes in FutureChem’s financial health indicators
    • • Analysis of global radiopharmaceutical market trends and competitors
    Q: What type of cancer does FutureChem’s [177Lu]Ludotadipep treat?

    A: It treats metastatic castration-resistant prostate cancer (mCRPC).

    Q: What stage is this clinical trial currently in?

    A: It is in Phase 3, the final stage before potential commercialization. Success in this phase is crucial for market approval.

    Q: How will this trial approval impact FutureChem’s stock price?

    A: It is likely to have a positive short-term impact. However, the long-term stock price will depend on the trial results and market conditions.

    FutureChem's Prostate Cancer Drug Enters Phase 3 Trial: Investment Analysis 관련 이미지
    FutureChem's Prostate Cancer Drug Enters Phase 3 Trial: Investment Analysis 관련 이미지

  • Syntekabio Issues ₩10B Convertible Bonds: Opportunity or Risk? Investor Analysis



    Syntekabio Issues ₩10B Convertible Bonds: Opportunity or Risk? Investor Analysis 대표 차트 이미지






    What Happened? Syntekabio Announces ₩10B Convertible Bond Offering

    Syntekabio has decided to issue ₩10 billion worth of convertible bonds to Sangsangin Savings Bank and Sejong Industrial. The payment date is September 12, 2025, and the conversion claim period is from September 12, 2026, to August 12, 2028.

    Why the Convertible Bond Issuance?

    Syntekabio urgently needs funding for the advancement of its AI drug discovery platform and expansion of its data center business. The company has been facing financial difficulties due to continuous operating losses and high debt-to-equity ratio, and this convertible bond issuance is intended to address the short-term liquidity crisis.

    What are the Potential Impacts?

    Positive Impacts:

    • Securing ₩10 billion for R&D investment and new business development
    • Expected stabilization of short-term liquidity and operations

    Negative Impacts:

    • Potential stock dilution upon future conversion to shares
    • Concerns about increased financial burden with an already high debt-to-equity ratio (190.47%)
    • Inevitable dilution of existing shareholders’ equity

    What Should Investors Do?

    Investors should proceed with caution. It’s crucial to closely monitor whether the secured funds will translate into tangible business results and how the company plans to improve its financial health. Investment decisions should be made considering the potential impact of the convertible bonds, particularly the possibility of stock dilution upon conversion if the share price rebounds.



    Frequently Asked Questions (FAQ)

    What are convertible bonds?

    Convertible bonds (CBs) are debt securities that can be converted into a predetermined number of shares of the issuing company’s common stock after a specified period.

    How will Syntekabio’s convertible bond issuance affect its stock price?

    In the short term, securing funding could create positive sentiment and potentially drive the stock price up. However, the long-term impact of potential stock dilution upon conversion needs to be considered.

    Should I invest in Syntekabio?

    Syntekabio possesses technological capabilities in AI drug discovery but faces significant financial instability. Investors should carefully consider these risks and closely monitor the company’s business performance and financial improvement efforts.









    Syntekabio Issues ₩10B Convertible Bonds: Opportunity or Risk? Investor Analysis 관련 이미지
    Syntekabio Issues ₩10B Convertible Bonds: Opportunity or Risk? Investor Analysis 관련 이미지




  • JPMorgan Acquires 5.16% Stake in Protina: Investment Analysis and Future Outlook

    JPMorgan Acquires 5.16% Stake in Protina: Investment Analysis and Future Outlook 대표 차트 이미지

    1. What Happened? JPMorgan Acquires 5.16% Stake in Protina

    JPMorgan Asset Management has acquired 513,000 shares of Protina, securing a 5.16% stake. While categorized as a passive investment, the move by a global investment giant is expected to significantly influence market perception.

    2. Why Did JPMorgan Invest in Protina? Strong Fundamentals and Growth Potential

    • Proprietary Technology: Protina possesses a competitive edge in the drug discovery and companion diagnostics market with its proprietary SPID platform technology. Its AI-driven antibody design technology is particularly noteworthy as a future growth engine.
    • Rapid Revenue Growth: Protina has demonstrated remarkable growth, with a 194% year-over-year increase in revenue in the first half of 2025. Long-term contracts with major clients and expansion into international markets are expected to create a stable revenue base.
    • Active R&D: Continuous investment in R&D, including securing key research personnel, winning government grants, and filing patents, strengthens Protina’s technological competitiveness.
    • KOSDAQ Listing: Protina’s successful listing on the KOSDAQ exchange in July 2025 through the special technology listing process has enhanced its corporate value and facilitated investment attraction.

    3. JPMorgan’s Investment: What are the Implications? Improved Investor Sentiment and Stock Price Momentum

    JPMorgan’s investment is expected to boost market confidence in Protina and improve investor sentiment. This is likely to translate into upward momentum for the stock price. The possibility of further investment from JPMorgan cannot be ruled out, potentially serving as a long-term growth catalyst.

    4. What Should Investors Do? Positive Outlook Requires Risk Management

    Given Protina’s promising growth outlook, it appears to be an attractive investment opportunity. However, continuous monitoring of potential risk factors, including profitability, cost management, and exchange rate volatility, is crucial. Investors should also stay informed about market conditions and adjust their investment strategies accordingly.

    What percentage of Protina’s shares did JPMorgan acquire?

    JPMorgan acquired a 5.16% stake in Protina.

    What is Protina’s main business?

    Protina is engaged in drug discovery and companion diagnostics based on its SPID platform technology.

    What are the key factors to consider when investing in Protina?

    Potential risks such as profitability, cost management, and exchange rate fluctuations should be considered.

    JPMorgan Acquires 5.16% Stake in Protina: Investment Analysis and Future Outlook 관련 이미지
    JPMorgan Acquires 5.16% Stake in Protina: Investment Analysis and Future Outlook 관련 이미지

  • Gemvax (082270) IR: In-Depth Analysis and Future Outlook for Investors

    Gemvax (082270) IR: In-Depth Analysis and Future Outlook for Investors 대표 차트 이미지

    1. What will be discussed at Gemvax’s IR?

    The main topics of this IR will be the progress of GV1001 development, explanation of the rights offering, and a Q&A session with investors. The focus will be on whether solutions will be presented for Gemvax’s biggest current issues: capital impairment and continuous operating losses.

    2. Why is Gemvax holding an IR?

    Gemvax is currently facing difficult circumstances. Its bio business (GV1001) carries high development risks, its environmental business is facing intensifying competition, and its financial status is marked by severe capital impairment. This IR is interpreted as an attempt to alleviate investor concerns, enhance understanding of the company, and improve investment sentiment.

    3. What will Gemvax’s future look like after the IR?

    • Positive GV1001 Development: Positive news regarding FDA orphan drug designation and clinical trials could create upward momentum for the stock price.
    • Successful Rights Offering: A clear explanation of the use of funds and measures to minimize dilution of existing shareholder value could have a positive impact.
    • Failure to Improve Financial Structure: Failure to present convincing solutions will likely lead to a decline in stock price.

    However, a worsening macroeconomic situation (fluctuations in exchange rates, interest rates, and oil prices) could negatively affect Gemvax.

    4. What should investors do?

    Investors should carefully analyze the information presented at the IR, paying close attention to the following:

    • Any positive updates regarding GV1001 development
    • The concreteness and validity of the rights offering fund utilization plan
    • Presentation of a roadmap for resolving capital impairment and improving financial structure

    It’s crucial to make cautious investment decisions by referring to market reactions and expert analysis after the IR.

    What are Gemvax’s main businesses?

    Gemvax’s main businesses are environmental pollution control and bio business (GV1001 drug development). They have also recently entered the waste plastic pyrolysis oil refining business.

    What is Gemvax’s financial status?

    There are significant concerns about Gemvax’s financial health due to high debt-to-equity ratio, continuous operating losses, and severe capital impairment.

    What is GV1001?

    GV1001 is a drug candidate being developed for the treatment of Alzheimer’s disease, Progressive Supranuclear Palsy (PSP), and other conditions.

    Gemvax (082270) IR: In-Depth Analysis and Future Outlook for Investors 관련 이미지
    Gemvax (082270) IR: In-Depth Analysis and Future Outlook for Investors 관련 이미지

  • QuantaMatrix Convertible Bond Exercise: Impact on Stock Price and Investment Strategy

    QuantaMatrix Convertible Bond Exercise: Impact on Stock Price and Investment Strategy 대표 차트 이미지

    Convertible Bond Exercise: What happened?

    QuantaMatrix announced that the conversion right for 220,166 convertible bonds (conversion price: KRW 4,542) will be exercised on September 15, 2025. This represents approximately 1.1% of the total market capitalization, raising concerns about stock dilution due to the increase in outstanding shares. The fact that the conversion right is being exercised at a time when the current stock price is lower than the conversion price could negatively impact investor sentiment.

    Why is this important?

    The exercise of convertible bonds is a significant event that affects both a company’s financial structure and stock price. On the positive side, a decrease in debt ratio and interest expense can be expected. However, on the negative side, there is a possibility of stock dilution and a decrease in EPS due to the increase in the number of outstanding shares. Especially for companies currently recording operating losses, such as QuantaMatrix, the exercise of convertible bonds is more likely to act as downward pressure on the stock price rather than improving financial soundness.

    Investment Strategies: What should investors do?

    Short-term investment strategy: It is advisable to take a wait-and-see approach, considering the possibility of increased stock price volatility due to the exercise of conversion rights. Careful investment decisions are required, paying attention to short-term downward pressure on stock prices.
    Mid- to long-term investment strategy: If you are confident in QuantaMatrix’s long-term growth potential, you may consider a strategy of dividing purchases when the stock price falls. However, it is necessary to continuously monitor whether profitability improves through future earnings announcements.

    Key Monitoring Points

    • Stock price movements and trading volume changes after conversion of convertible bonds
    • Sales performance of dRAST and QMIA products
    • Performance of entering the Alzheimer’s diagnosis market
    • Efficiency of R&D expenses and SG&A expenses

    Frequently Asked Questions

    What are convertible bonds?

    Convertible bonds are issued in the form of bonds, but they are granted the right to be converted into the issuing company’s stock under certain conditions.

    Does the exercise of convertible bonds only have a negative impact on the stock price?

    Not necessarily. While there are positive effects such as a decrease in the debt ratio and interest expense, the possibility of stock dilution due to an increase in the number of outstanding shares should also be considered.

    What should I be aware of when investing in QuantaMatrix?

    You should continuously monitor factors such as profitability improvement, new business entry performance, and financial soundness.

    QuantaMatrix Convertible Bond Exercise: Impact on Stock Price and Investment Strategy 관련 이미지
    QuantaMatrix Convertible Bond Exercise: Impact on Stock Price and Investment Strategy 관련 이미지

  • 3Billion IR: Q2 2025 Earnings and the Path to Profitability

    3Billion IR: Q2 2025 Earnings and the Path to Profitability 대표 차트 이미지

    1. 3Billion’s IR: What Was Discussed?

    3Billion’s IR meeting focused on the company’s Q2 2025 financial results and its strategy for future growth. The key takeaways centered around their recent performance and plans for achieving profitability.

    2. Why It Matters: Balancing Growth and Losses

    3Billion has demonstrated remarkable revenue growth, capitalizing on the expanding rare disease diagnostics market and achieving significant international expansion. However, high R&D and fixed costs have resulted in continued losses. The IR meeting’s focus on profitability strategies is therefore crucial for investors. Addressing the company’s increasing debt is also essential.

    3. The Potential Outcomes: IR Impact Scenarios

    A clear and achievable profitability plan presented during the IR meeting could alleviate market concerns and drive stock prices upward. Conversely, disappointing results or a vague profitability strategy could negatively impact investor confidence and lead to a decline in share value.

    4. Investor Action Plan: Key Checkpoints

    • Review Q2 2025 earnings and profitability trends.
    • Assess the specific plans and timelines for achieving profitability.
    • Evaluate the scalability and revenue generation plan for the SaaS business.
    • Gather information on AI technology advancements and new pipelines.
    • Analyze debt management and capital raising plans.
    • Review strategies for managing foreign exchange volatility.

    Frequently Asked Questions

    What is 3Billion’s core business?

    3Billion provides rare disease diagnostic services using its AI-powered genomic analysis technology, ‘GEBRA’, covering over 8,000 rare diseases.

    What are 3Billion’s competitive advantages?

    3Billion boasts AI-driven automated interpretation technology, a global network spanning over 70 countries, 43 patents, 131 publications, and awards from AI competitions, demonstrating strong R&D capabilities.

    What is 3Billion’s current financial situation?

    While revenue is growing rapidly, the company is currently operating at a loss due to high R&D and fixed costs. The increasing debt-to-equity ratio should also be monitored closely.

    3Billion IR: Q2 2025 Earnings and the Path to Profitability 관련 이미지
    3Billion IR: Q2 2025 Earnings and the Path to Profitability 관련 이미지

  • DuChemBio IR Analysis: Stock Forecast After 2025 KB Korea Conference Presentation

    DuChemBio IR Analysis: Stock Forecast After 2025 KB Korea Conference Presentation 대표 차트 이미지

    1. DuChemBio IR: What Was Discussed?

    On September 3, 2025, DuChemBio presented its company overview, current management status, and future outlook at the KB Korea Conference. They emphasized their high market share in the domestic PET-CT radiopharmaceutical market with key products like FDG, FP-CIT, and Amyloid PET, and explained their portfolio expansion strategy through new product launches (e.g., FES). Overseas technology transfer, open innovation, and the acquisition of RadioDNS Labs to strengthen R&D capabilities were also highlighted. The solid financial performance for the first half of 2025 (revenue of KRW 17.96 billion and operating profit of KRW 2.55 billion) was also announced.

    2. Why Invest in DuChemBio?

    DuChemBio has high growth potential alongside the growth of the radiopharmaceutical market. Its key competitive advantages include high market share, strong technological capabilities, and active R&D investments. This IR provided investors with a clear understanding of the company’s vision and growth strategy. Furthermore, participation in the KB Korea Conference is expected to increase brand awareness and attract potential investors.

    3. Post-IR Stock Forecast: What to Expect?

    The IR is expected to have positive impacts, such as enhancing investor confidence and brand awareness, building a positive corporate image, and expanding future funding and partnership opportunities. However, potential risk factors, including the content of the IR and Q&A session, macroeconomic volatility, and intensifying competition, must also be considered. While a positive stock trend is expected overall, continuous monitoring of market conditions and the competitive landscape is necessary.

    4. Investor Action Plan

    • Closely monitor the IR presentation content and market reaction.
    • Analyze the impact of macroeconomic variables (interest rates, exchange rates, oil prices, etc.).
    • Continuously observe the progress of the R&D pipeline and new market development efforts.
    What is DuChemBio’s main business?

    DuChemBio’s main business is the development, manufacturing, and sale of radiopharmaceuticals for the diagnosis and treatment of cancer and brain diseases.

    What are DuChemBio’s competitive advantages?

    DuChemBio holds a high market share in the domestic PET-CT radiopharmaceutical market and strengthens its technological competitiveness through continuous R&D investment.

    What is DuChemBio’s future growth strategy?

    DuChemBio secures growth drivers through new product launches, overseas technology transfer, open innovation, and strategic acquisitions.

    DuChemBio IR Analysis: Stock Forecast After 2025 KB Korea Conference Presentation 관련 이미지
    DuChemBio IR Analysis: Stock Forecast After 2025 KB Korea Conference Presentation 관련 이미지